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Communicable disease is a misnomer.  The disease is not communicable; the microbe 
mainly associated with the disease is communicable.  Whether the recipient of the microbe 
develops the disease depends on the health of the recipient’s immune system.  Our model of 
COVID-19 development starts with real-life exposures to multiple toxic stressors degrading the 
immune system.  This is followed by the SARS-CoV-2 virus exploiting the degraded immune 
system to trigger a chain of events ultimately leading to COVID-19. 
To prevent or treat infectious disease, the health of the immune system must be 
maintained or improved.  One major component of maintaining and improving immune system 
health is removal of those factors that contribute to immune system degradation.  A previous 
monograph identified many factors that contribute to immune system degradation (Contributing 
Factors (CFs)).  It was hypothesized that many of these CFs to immune system degradation were 
identical to those that past studies have shown were CFs to chronic diseases.  
To test this hypothesis, a proof-of-principle demonstration was performed to identify the 
commonality between CFs to immune system degradation and CFs to Parkinson’s Disease (PD).  
A very streamlined approach was used, and approximately 500 CFs were found in common 
between the two diseases. Since COVID-19 (and other infectious diseases) results from immune 
system degradation in our model, this means COVID-19 and PD are enabled by many of the 
same toxic exposures and toxic behaviors.  Thus, many of the measures required to strategically 
treat and prevent infectious diseases are similar to those required to strategically treat and 
prevent chronic diseases.  This is a major paradigm shift for orthodox Western medicine, but is 
required to achieve major advances in global population health. 
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Diseases are generally divided into two classes: communicable and non-communicable 
[1]. 
Communicable diseases may be defined as follows: “Communicable diseases, also 
known as infectious diseases or transmissible diseases, are illnesses that result from the infection, 
presence and growth of pathogenic (capable of causing disease) biologic agents in an individual 
human or other animal host” [2]. 
Examples of communicable diseases include COVID-19, Severe Acute Respiratory 
Syndrome (SARS), influenza, etc. 
Non-communicable diseases may be defined as follows: “A noncommunicable disease 
(NCD) is a medical condition or disease that is by definition non-infectious and non-
transmissible among people” [3]. 
Examples of non-communicable diseases include cancer, chronic kidney disease (CKD), 
Parkinson’s disease (PD), Alzheimer’s disease (AD), etc. 
 
Misrepresentation of Communicable Diseases 
Despite widespread usage of the term, "communicable disease" is a misnomer.  The 
disease is not communicable, the virus(es)/microbe(s) mainly associated with the disease is 
communicable.  Whether the disease results from the transmitted virus/microbe, and most 
especially whether serious consequences result from the transmitted virus/microbe, depends on 
the health of the virus/microbe recipient's immune system [4-5]. 
The distinction between communicable disease and communicable virus goes well 
beyond semantics, and is extremely important for prevention and treatment of these diseases.  
For a virus-associated disease (such as COVID-19), if the disease were actually communicable, 
then prevention/treatment would have to be virology-focused, such as quarantine, face masks, 
anti-viral drugs, antiviral vaccines, etc. [4-6]. 
In our model, COVID-19 results from the effective exploitation of a degraded immune 
system by the SARS-CoV-2 virus, with the exploitation process outlined as follows: COVID-19 
development starts with real-life exposures to multiple toxic stressors degrading the immune 
system. This is followed by the inability of the degraded immune system to neutralize the SARS-
CoV-2 virus, thereby allowing the virus to enter and replicate in the cell and trigger a chain of 
events ultimately leading to COVID-19 [4-6]. 
If immune system degradation is a/the major factor in the severity of disease, then 
prevention/long-term treatment requires eliminating those factors that contribute to the 
degradation of the immune system.  The virology-centric approach used currently would need to 
be strongly supplemented by a toxicology-centric approach, whose evidentiary basis would 
require going beyond current single-stressor laboratory experiments to more comprehensive 












Over-Emphasis on Virology; Under-Emphasis on Toxicology 
Unfortunately, much of communicable disease medical research sponsored by the 
government and industry, and some foundations, focuses on the virology and ignores the 
toxicology aspects.  The research attempts to find ‘magic bullets’ that will suppress viral 
transmission and resultant infection without producing severe side-effects. From a toxicology-
centric perspective, so-called communicable and non-communicable diseases are intrinsically 
almost identical when it comes to prevention and reversal.  Consider Alzheimer’s disease (AD) 
or Parkinson’s disease (PD) and Coronavirus Disease 19 (COVID-19), for example, since our 
group has studied these diseases in some detail [6, 8].  AD and PD are driven by degradation of 
the neural system (Cognitive functioning for AD, and Motor functioning for PD), and COVID-
19 is driven by degradation of the immune system.  Essentially the same factors that contribute 
to the degradation of the neural system also contribute to degradation of the immune system, as 
the next section will show for the example of PD and immune system degradation. 
  





COMMONALITY OF CONTRIBUTING FACTORS (CFs) TO PD AND COVID-19 
(IMMUNE SYSTEM DEGRADATION) 
 
Background 
Our group has been developing protocols to prevent and reverse chronic diseases [8-10].  
The central component of our approach is identification and elimination of CFs to these myriad 
chronic diseases.  The question arises: can our central component for preventing and reversing 
chronic diseases be applied successfully to preventing and reversing so-called communicable 
diseases, such as COVID-19? 
In our model, COVID-19 results from the effective exploitation of a degraded immune 
system by the SARS-CoV-2 virus; therefore, CFs to a degraded immune system are CFs to 
COVID-19.  In the present section, we identify CFs to PD (which we are studying at present) and 
immune system degradation (which we are also studying presently), and show their commonality 
using a very streamlined approach.  The importance of this commonality means that many of the 
factors that are contributing to PD are also contributing to COVID-19, and elimination of these 
common factors (as well as other CFs not in common) would contribute substantially to 
preventing or reversing these serious diseases.  In this respect, these two superficially different 
diseases are in actuality two heads of the same Hydra (a multi-headed serpentine water monster 
from Greek mythology)! 
It should be noted that CF commonality between PD and COVID-19 is one of potentially 
multiple commonalities between the two diseases, although it is an extremely important 
commonality from the perspective of prevention and treatment.  In 2014, the first author 
published a study showing theme commonalities between PD (neurodegenerative) and Crohn’s 
Disease (autoimmune) using phrase matching between the two disease literatures and 
bibliographic coupling between the two literatures (shared references) [11].  Because of the 
strong emphasis on shared references, the commonality at a more fundamental mechanism level 
was demonstrated.  Combining these two approaches for identifying commonality (CF 
commonality and bibliographic coupling/phrase matching) could provide deeper understanding 
at different levels of commonality.  The present study focused on CF commonality only. 
 
Methodology 
 The streamlined method used for this study is termed a dot-product approach.  Lists of 
known toxic substances were aggregated from myriad (mainly) government agencies, and 
combined with lists of CFs identified in our previous disease studies.  This produced a final list 
of over 14,000 potential CFs to disease.  While this is certainly a large number of potential CFs, 
it undoubtedly omits additional CFs that a well-resourced study could have identified. 
 A core literature query was defined for PD, applied to Pubmed, and the resultant retrieval 
was imported into VantagePoint software [12].  The title and abstract phrases of the retrieved 
records were parsed, resulting in lists of many phrases.  The same procedure was followed for 
the immune degradation core literature [6, app. 4]. 
 The external list of >14,000 phrases of potential CFs was intersected with the parsed list 
of abstract phrases in the PD and immune degradation core literatures.  These two intersected 
lists were compared, and the CFs in common were identified.  Over 500 CFs in common were 
identified, albeit some being variants of the same concept.  However, this is a very conservative 
estimate of CFs in common, for the following reasons. 





 First, only CFs that occurred within the PD and immune system degradation core 
literatures were used.  Thus, if a candidate CF was shown to enhance oxidative stress, and 
enhanced oxidative stress was a marker of PD or immune degradation, the candidate CF became 
a confirmed CF if the article that showed the linkage to CF was in the PD or immune degradation 
core literature.  If the candidate CF enhanced, say, “oxidative stress,” but the article(s) that 
showed this linkage was not in the PD or immune degradation core literature, then the candidate 
CF did not become a confirmed CF.  Given that “oxidative stress” occurs in 2200 abstracts in the 
PD literature used for the present study, and about 230,000 abstracts in the total Medline 
database, these indirect impacts that require merging of two records (impact of CF on oxidative 
stress; impact of oxidative stress on PD) have the potential to expand the number of records in 
common substantially. 
 Some of the more general biomarkers in common between PD and immune degradation 
include inflammation, apoptosis, oxidative stress, cell death, pro-inflammatory cytokines, 
anemia, lipid peroxidation, plaque, oxidative damage, reduced glutathione, DNA fragmentation, 
insulin resistance, NF-kappaB activation, hypertrophy, free radicals, ROS generation, 
neurodegeneration, mitochondrial dysfunction, demyelination, caspase-3 activation, microglial 
activation, neuronal loss, tyrosine phosphorylation, cellular damage, gliosis, arterial 
hypertension, mitochondrial damage, astrogliosis, brain damage, excitotoxicity, protein 
phosphorylation, hyperphosphorylation, membrane permeability, nitrosative stress, protein 
degradation, axonal degeneration, mitochondrial depolarization, mitochondrial fragmentation, 
cholinergic deficits, metabolic stress, neurofibrillary degeneration, nigrostriatal degeneration, 
protein folding, etc.  If indirect impacts, as defined above, had been included, much larger 
numbers of both CFs and commonalities would have resulted. 
 Second, the core immune degradation literature (as defined by our query) was relatively 
small compared to the PD core literature (and other chronic disease core literatures we have 
retrieved).  A more comprehensive query would have retrieved a much larger literature, with 
many hundreds more CFs to immune degradation. 
Third, all the matching and dot product operations required exact phrase matching.  The 
slightest difference between any two phrases meant neither phrase survived the dot product 
process.  Given the disagreements on phrase representations among the toxic substance list 
providers for identical concepts, especially chemical formulas, and the subsequent disagreements 
between the external phrases and the parsed phrases of the Pubmed retrievals, we estimate many 
hundreds of phrases in common were lost.  The fact that ~500 common phrases survived is 
testament to the potentially large commonality between the CFs to PD and COVID-19.  We 
would expect similar results between COVID-19 and most (if not all) chronic diseases, based on 
the findings in our Pervasive Causes of Disease eBook [13]. 
Fourth, in order for a toxic substance or behavior to have been included in the core 
literature for PD or COVID-19, it had to have been researched and reported in Medline.  Given 
the large number of potential toxic substances and behaviors possible [13], and the limited 
number of biomarkers used in experiments to identify their adverse effects, the limited number 
of toxic substance/behavior-disease combinations studied will limit the number of potential CFs 
that enter any disease core literature, and therefore will limit the number of CFs in common 









Results and Discussion 
 
Results 
Fifty of the ~500 common CFs were selected for validation, and are presented in Table 1, at the 
end of the present section.  They span the five-category taxonomy we have developed for 
classifying CFs to disease: Lifestyle, Iatrogenic, Biotoxins, Occupational/Environmental, 
Psychosocial/SocioEconomic [8].  We do not include Genetics, since the CFs in our definition 
are viewed as foundational, meaning they are somewhat under our control. 
 The fifty CFs in Table 1 were validated as follows.  To validate a CF to PD, the candidate 
CF was intersected with the PD core literature query in Pubmed, and the retrieved records were 
examined.  If a record’s title or abstract showed a link between the candidate CF and some 
representation of PD, the CF and reference were entered into Table 1.  The same procedure was 
followed with a slightly generalized version of the immune degradation core literature query.  
The detailed record excerpts showing these linkages are presented in Appendix 1. 
 What is a ‘representation’ of PD or immune degradation, as mentioned above?  
‘Representations’ of PD are biomarkers characteristic of PD (e.g., Parkinson's disease; Parkinson 
Disease; alpha-synuclein; Lewy bodies; Subthalamic Nucleus; neurodegenerative; dyskinesia; 
Degeneration; Neurodegeneration; Neurotoxicity; Movement Disorders; cognitive impairment; 
supranuclear palsy; oxidative stress; dystonia; essential tremor; freezing of gait; cell death; 
apoptosis; mitochondrial dysfunction; dopaminergic neurodegeneration; Autonomic dysfunction; 
cognitive dysfunction; motor impairment; olfactory dysfunction; Motor Dysfunction; 
dopaminergic degeneration; dopaminergic neurotoxicity; dopaminergic dysfunction; memory 
impairment; tau pathology; phosphorylated tau, etc.).  While some of these biomarkers apply to 
other diseases, it should be remembered they were located in records that had PD as their main 
theme, so their use was in the context of PD. 
 ‘Representations’ of immune degradation are biomarkers characteristic of immune 
degradation or components of the immune system that are being degraded (e.g., immunotoxicity; 
immunotoxic; spleen; immunosuppression; lymphocytes; immunosuppressive; inflammatory; 
cytokines; infection; macrophages; T cells; apoptosis; immunoglobulin; Thymus; 
hypersensitivity; oxidative stress; T-cell; cytotoxicity; cytotoxic; autoimmune; splenocytes; T 
cell; bone marrow; reactive oxygen species; immune suppression; neutrophils; cell death; 
neurotoxicity; immunodeficiency; thymocytes; lipid peroxidation; autoimmunity; pro-
inflammatory cytokines; T-lymphocyte; natural killer cell; oxidative damage; immune 
dysfunction; white blood cell; red blood cell; cell apoptosis; impaired immune; immune 
alterations, etc.).  Again, while some of these biomarkers apply to other diseases, it should be 
remembered they were located in records that had immune degradation as their main theme, so 
their use was in the context of immune degradation. 
 
Discussion 
 Alteration of natural and pathological autoimmunity appears to be the thread connecting 
processes/agents related to PD and immune degradation. This is in keeping with the fact that PD 
has a tight connection with a long list of autoimmune diseases, such as type 1 diabetes, Crohn 
disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, multiple sclerosis, 
amyotrophic lateral sclerosis, Graves/hyperthyroidism, Hashimoto/hypothyroidism, pernicious 
anemia, and polymyalgia rheumatic [14-15].  Such PD autoimmune context appears to underlie 





and link together, one-by-one, CFs and immune degradation as listed in Table 1.  A few 
examples from Category 1 are: 
 
Advanced Glycation End Products (Table 1, Row 1) 
- advanced glycation end (AGE) products may activate NLRP3 inflammasome [16]. Altered 
NLRP3 inflammasome may lead to autoimmune diseases including rheumatoid arthritis, 
systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, and ankylosing 
spondylitis [17]. 
 
Cocaine (Table 1, Row 3) 
- cocaine may interfere with immune recognition of α-synuclein by anti-α-synuclein natural 
autoantibodies (NAAbs). Under physiological conditions, anti-α-synuclein NAAbs prevent 
aggregation and clumping of α-synuclein, a protein that, when aggregated, accumulates as Lewy 
bodies in the brains of people with PD [18-19]. Consequently, naturally occurring α-synuclein 
autoantibody levels are lower in patients with Parkinson disease [20].  Possible interference of 
cocaine with the immune protection of α-synuclein by NAAbs derives from the fact that cocaine 
binds tightly to N-terminus of intrinsically unstructured α-synuclein that adopts a more compact 
folded conformation, thus increasing the likelihood of α-synuclein structure misfolding [21-22], 
immune mis-recognition, and clumping. 
 
Gluten (Table 1, Row 4) 
- gluten toxicity might extend to the nervous system and contribute to PD via cross-reactive 
autoimmunity. As a matter of fact, gliadin protein – a component of gluten protein complex - 
presents a  single amino acid repeat  (QQQQQQQQQQQQ) that is also present in numerous 
human proteins related to neurodegeneration (ie, Voltage-dependent P/Q-type calcium channel 
subunit alpha-1A, Huntingtin, DNA polymerase subunit gamma-1, Ataxin-1, Ataxin-8, 
Atrophin-1 among others) and alterations of which lead to spinocerebellar ataxia, frontotemporal 
degeneration, Huntington disease, cognitive impairment, aphasia and oculomotor apraxia, inter 
alia [23]. 
 
High-Fat Diet (Table 1, Row 5) 
- an autoimmune link between high fat diet and immunity degradation emerges from the fact that 
a high fat diet rich in saturated fatty acids induces inflammation in part by mimicking the actions 
of lipopolysaccharide (a very potent stimulus of inflammatory responses), with bioactivity in the 
microgram per liter concentration range [24]. Of interest, lipopolysaccharide is an adjuvant that 
stimulates autoimmune responses [25] and has been used to establish a bacterial endotoxin-based 
experimental model of PD [26]. 
 
Methamphetamine (Table 1, Row 7) 
- methamphetamine has a double link with immune degradation, PD, and autoimmunity. Firstly, 
methamphetamine has a secondary amine that can start the Maillard reaction and lead to 
methamphetamine-conjugated AGE products [27], with consequent NLRP3 inflammasome 
activation and consequent autoimmune pathologies as described above [16-17]. Then, in 
addition, methamphetamine can bind to α-synuclein and cause a more compact conformation 
[28] with consequent immune mis-recognition and α-synuclein clumping. In this way, 
methamphetamine reproposes the cocaine pathological scheme: a drug binding to α-synuclein 





that increases the likelihood of misfolding and, possibly, interferes with the protective 
solubilization activity of anti- α-synuclein NAAbs [18-20].  As a direct consequence, this would 
increase the incidence of PD. 
 The commonality of the broad spectrum of contributing factors presented in Table 1 
shows that many of the factors responsible for the emergence of PD are also responsible for 
degrading the immune system and enabling the broad panorama of infectious diseases, including 
COVID-19.  A larger and more well-resourced study that included more potential CFs than the 
14,000+ used for the present study, and allowed for a concept-matching approach rather than a 





TABLE 1 – Common Contributing Factors to PD and Immune Degradation/COVID-19 






Advanced Glycation End Products 1 [29] [30] 
Alcohol Abuse 1 [31] [32] 
Cocaine 1 [33] [34] 
Gluten 1 [35] [36] 
High Fat Diet 1 [37] [38] 
Malnutrition 1 [39] [40] 
Methamphetamine 1 [41] [42] 
Sedentary 1 [43] [44] 
Vitamin D Deficiency 1 [45] [46] 
Bleomycin 2 [47] [48] 
Carboplatin 2 [49] [50] 
Cyclophosphamide 2 [51] [52] 
Halothane 2 [53] [54] 
Isoflurane 2 [55] [56] 
Thalidomide 2 [57] [58] 
Borrelia Burgdorferi 3 [59] [60] 
CMV 3 [61] [62] 
Epstein-Barr Virus 3 [63] [64] 
2,3,7,8-tetrachlorodibenzo-p-dioxin 4 [65] [66] 
Acrolein 4 [67] [68] 
Air Pollution 4 [69] [70] 
Aluminum 4 [71] [72] 
Arsenic 4 [73] [74] 
Atrazine 4 [75] [76] 
Cadmium 4 [77] [78] 
Carbon Monoxide 4 [79] [80] 
Carbon Tetrachloride 4 [81] [82] 





Chlorpyrifos 4 [83] [78] 
Cobalt 4 [84] [85] 
Copper Sulfate 4 [86] [87] 
Dichlorodiphenyltrichloroethane 4 [88] [89] 
Hexachlorobenzene 4 [90] [91] 
Inorganic Dust 4 [92] [93] 
Lead 4 [94] [95] 
Manganese 4 [96] [97] 
Mercury 4 [98] [99] 
N-hexane 4 [100] [101] 
Nitrogen Dioxide 4 [102] [103] 
Polychlorinated Biphenyls 4 [104] [105] 
Perchloroethylene 4 [81] [106] 
Polybrominated Diphenyl Ethers 4 [107] [108] 
Power Frequency EMF 4 [109] [110] 
Radiofrequency EMF 4 [111] [112] 
Radiotherapy 4 [113] [114] 
Silica 4 [115] [116] 
Titanium Dioxide 4 [117] [118] 
Trichloroethylene 4 [119] [120] 
Chronic Restraint Stress 5 [121] [122] 
Depression 5 [123] [124] 
Life Stress 5 [125] [126] 
Posttraumatic Stress 5 [127] [128] 
CATEGORY CODE: 1=LIFESTYLE; 2=IATROGENIC; 3=BIOTOXINS; 
4=OCCUPATIONAL/ENVIRONMENTAL; 5=PSYCHOSOCIAL/SOCIOECONOMIC 
  





NEW PARADIGM REQUIRED FOR PREVENTING AND TREATING INFECTIOUS 
AND CHRONIC DISEASES 
 
Mainstream Medical Approach for “Magic Bullets” to Cure Disease 
The mainstream medical focus on PD/AD and COVID-19 is searching for a ‘magic 
bullet’ that will "cure" the patient.  For PD/AD, it's some sort of ‘magic drug’, whereas for 
COVID-19, it's some sort of a ‘magic vaccine’.  As Bredesen (AD expert) stated: "In the case of 
Alzheimer’s disease, there is not a single therapeutic that exerts anything beyond a marginal, un-
sustained symptomatic effect, with little or no effect on disease progression. Furthermore, in the 
past decade alone, hundreds of clinical trials have been conducted for AD, at an aggregate cost of 
billions of dollars, without success. This has led some to question whether the approach taken to 
drug development for AD is an optimal one [129]."  That statement could apply in different 
degrees to myriad chronic diseases.  In fact, it is challenging to identify a chronic disease to 
which that statement does not apply! Bredesen’s statement is applicable to some (perhaps many) 
infectious diseases as well.  For example, since the initial SARS outbreak in 2002, many 
coronavirus vaccine developments have been attempted, and none have succeeded [6]. 
For PD/AD and COVID-19, the researchers/politicians have the belief that some ‘magic 
bullet’ can compensate for the adverse effects produced by hundreds of CFs to the disease.  
Conceptually, how is this possible?  The symptoms of PD/AD and COVID-19 are warning 
signals that something is out of kilter, similar to the oil warning light on a car’s dashboard.  
Addressing only the symptoms with some drug or vaccine in isolation (akin to altering the oil 
warning light without addressing the underlying reasons why it is lit) can only lead to more 
serious consequences, if the fundamental causes are not addressed.  Addressing the fundamental 
causes in parallel with a drug or vaccine would increase the efficacy of each; in fact, addressing 
the fundamental causes could potentially preclude the necessity for drugs or vaccines in 
preventing/treating these diseases. 
 
Major Medical Paradigm Shift Required 
The findings of the present study suggest a paradigmatic shift in medical approaches to 
disease.  The current approach to both ‘communicable’ and non-communicable diseases is 
mainly (not exclusively) external-treatment-based; i.e., taking some additive action (providing a 
drug, vaccine, radiation, surgery, etc.) to alleviate/reduce symptoms/abnormal biomarkers 
without sufficiently addressing the myriad factors that enabled the disease to emerge.  The 
approach suggested by the findings in the present study is centered on identifying the factors that 
contributed to the disease, and eliminating these factors as comprehensively, thoroughly, and 
rapidly as possible.  If CF elimination by itself is insufficient to prevent/reverse the disease 
completely, then some type of external treatment may be included, and in fact may be more 
efficacious with the elimination of the CFs.  But, in both cases, healing must center around CF 
elimination, with external treatment used if healing does not proceed as rapidly as desired (e.g. 
the first step to heal a burn is to remove the heat source prior to treatment). 
  







 Communicable disease is a misnomer.  The disease is not communicable; the microbe 
mainly associated with the disease is communicable.  Whether the recipient of the microbe 
develops the disease depends on the health of the recipient’s immune system. 
Thus, to prevent or treat infectious disease, the health of the immune system must be 
improved.  One major component of increasing immune system health is to remove those factors 
that contribute to immune system degradation.  A previous monograph identified many CFs to 
immune system degradation [6].  It was hypothesized that many of these CFs to immune system 
degradation were identical to those that past studies have shown were CFs to chronic diseases [8-
10]. 
To test this hypothesis, a proof-of-principle demonstration was performed to identify the 
commonality between CFs to immune system degradation and CFs to PD.  A very streamlined 
approach was used, and approximately 500 CFs were found in common between the two 
diseases. Since COVID-19 (and other infectious diseases) results from immune system 
degradation, this means COVID-19 and PD are enabled by many of the same toxic exposures 
and toxic behaviors (some toxic behaviors, such as choosing to smoke cigarettes, also involve 
toxic exposures, whereas others, such as sedentary living, do not).  Thus, many of the measures 
required to strategically treat and prevent infectious diseases are similar to those required to 
strategically treat and prevent chronic diseases.  This is a major paradigm shift for orthodox 
Western medicine, but is required to achieve major advances in global population health. 
Realistically, very few people are willing to make the sacrifices required to eliminate the 
CFs to these myriad diseases, and thereby prevent or reverse these diseases.  Decision-makers 
realize this, and continue to promote and sponsor the non-toxicology approaches for preventing 
and reversing both communicable and non-communicable diseases, even though these 
approaches have had very limited success. 
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Commonality of Contributing Factors between PD and Immune System Degradation – Details 
 
Category 1 
Advanced Glycation End Products 
PD: “Immunolocalization of advanced glycation end-products and a marker of oxidative stress 
response induction provides evidence that glycoxidation and oxidative stress may be an 
important pathogenic factor in diseases characterized by Lewy body formation, and 
furthers the evidence that cytoskeletal proteins and their inclusions are susceptible to 
oxidative stress.” [29] 
ID: “Advanced glycation end products impair NLRP3 inflammasome-mediated innate immune 
responses in macrophages” [30] 
Alcohol Abuse 
PD: “A history of an alcohol use disorder conferred an increased risk of admission with a 
diagnosis of Parkinson's disease in both women and men. In particular, the risk seemed 
higher at lower ages of first admission with Parkinson's disease.” [31] 
ID: “Alcoholism causes alveolar macrophage zinc deficiency and immune dysfunction” [32] 
Cocaine 
PD: “found that exposure to cocaine both in utero or as adults did not affect substantia nigra cell 
number, but did make these neurons more susceptible to the parkinsonian toxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine.” [33] 
ID: “based on in vivo experiments with the protozoan Tetrahymena, suggests the compromised 
immune response in cocaine addicts and assures the reported effects of cocaine on immune 
cell function.” [34] 
Gluten 
PD: “Dramatic improvement of parkinsonian symptoms after gluten-free diet introduction in a 
patient with silent celiac disease” [35] 
ID: “CGM negatively affected the gut health of turbot by inducing enteritis and by decreasing 
intestinal immunity and antioxidant capacity” [36] 
High Fat Diet 
PD: “Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat 
diet” [37] 
ID: “High-fat diet-derived free fatty acids impair the intestinal immune system and increase 
sensitivity to intestinal epithelial damage” [38] 
Malnutrition 
PD: “Under-nutrition is a problem for around 15% of community dwelling people with PD” 
[39] 
ID: “Malnutrition is the primary cause of immunodeficiency worldwide and profoundly affects 
immune responses.” [40] 
Methamphetamine 
PD: “Studies have implicated methamphetamine exposure as a contributor to the development 
of Parkinson's disease.” [41] 
ID: “METH exposure results in altered T cell cycle entry and progression.” [42] 
Sedentary 





PD: “data suggest that treadmill exercise throughout life can markedly reduce the chances of 
dopamine decrease, reinforcing studies that showed a lower incidence of Parkinson's 
disease in patients who were active during life.” [43] 
ID: “Sedentary lifestyle leads to the accumulation of visceral fat. This is accompanied by the 
infiltration of immune cells with pro-inflammatory characteristics in adipose tissue, causing 
an increased release of cytokines and generating a low-grade inflammatory state.” [44] 
Vitamin D Deficiency 
PD: “Reduced exposure to sunlight and low food intake can lead to vitamin D deficiency. 
Increasing evidence highlights the impact of vitamin D deficiency as a favoring factor in 
various central or peripheral neurological diseases, especially multiple sclerosis and several 
neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson's disease and 
Alzheimer's disease.” [45] 
ID: “Vitamin d deficiency reduces the immune response, phagocytosis rate, and intracellular 




PD: “Removal of alpha-synuclein in human cells leads to increased DNA double-strand break 
(DSB) levels after bleomycin treatment and a reduced ability to repair these DSBs” [47] 
ID: “Increased bleomycin-induced chromosome damage in lymphocytes of patients with 
common variable immunodeficiency indicates an involvement of chromosomal instability 
in their cancer predisposition” [48] 
Carboplatin 
PD: “Progression of Parkinson's disease with impairment of vision under 
carboplatin/cyclophosphamide therapy for ovarian cancer” [49] 
ID: “Carboplatin-induced immune hemolytic anemia” [50] 
Cyclophosphamide 
PD: “Our cases of chemotherapy-induced parkinsonism occurred after exposure 
to…..cyclophosphamide …by alkylating and cross-linking DNA…..Cyclophosphamide 
and ara-C are the most commonly implicated agents” [51] 
ID: “Cyclophosphamide did not affect body mass or packed cell volume. However, spleen to 
body mass ratios and the number of viable spleen cells were lower in CY-treated birds 
when compared to controls. Peripheral white blood cell numbers were reduced in CY-
treated starlings, and the decrease affected all cell types. Phagocytic ability of macrophages 
cultured from peripheral blood monocytes was impaired in cells from CY-treated birds. 
Additionally, CY treatment resulted in decreased lymphocyte blastogenesis to the T-cell 
mitogen Concanavalin A. The hemagglutination response to sheep erythrocytes was lower 
in birds that had received CY. Thus, these immunological methods detected chemically-
induced immune dysfunction in starlings” [52] 
Halothane 
PD: “Numerous recent mechanistic studies (in vitro essays and in vivo short-term studies) 
strengthened the association between exposure to anesthetic gases (nitrous oxide, 
halothane, isoflurane, levoflurane) and PD.” [53] 
ID: “halothane anesthesia potentiates the suppression of cell-mediated immunity observed in 
tumor-bearing hosts.” [54] 
Isoflurane 





PD: “Because the transport of dopamine by synaptosomes is impaired during and after exposure 
to halothane or isoflurane, [19] there may be decreased dopaminergic transmission as well 
as accumulation of extracellular dopamine during inhalational anesthesia because of 
simultaneous dopaminergic receptor blockade and depressed neuronal release and reuptake 
of dopamine.” [55] 
ID: “isoflurane anesthesia disrupts hippocampal neuroimmune mediator gene expression in the 
old brain and suggests a potential mechanism by which general anesthesia can contribute to 
disordered neuronal homeostasis and post-anesthesia cognitive disability in older subjects.” 
[56] 
Thalidomide 
PD: “Thalidomide induced acute worsening of Parkinson's disease”) [57] 
ID: “thalidomide prevents antiplatelet antibody-mediated platelet destruction in ITP mouse 




PD: “IB consisting of CMV, EBV, HSV-1, B. burgdorferi, C. pneumoniae and H. pylori is 
associated with PD. This study supports the role of infection in the etiology of PD.” [59] 
ID: “B. burgdorferi induced significantly greater monocyte activation and inflammatory 
cytokine production than did borrelial lysates or T. pallidum, and only B. burgdorferi 
elicited gamma interferon (IFN-gamma) from NK cells” [60] 
CMV(Cytomegalovirus) 
PD: “found higher frequencies of myeloid DCs with a pro-inflammatory CD16+ILT2(high) 
phenotype in CMV-positive PD patients than controls, suggesting the potential 
involvement of CMV in exacerbating PD.” [61] 
ID: “HIV-infected individuals are almost universally co-infected with cytomegalovirus (CMV) 
and both viruses are associated with inflammation-related morbidities.” [62] 
Epstein-Barr Virus 
PD: “Postencephalitic parkinsonism and basal ganglia necrosis due to Epstein-Barr virus 
infection” [63] 




PD: “TCDD induces UbcH7 expression and synphilin-1 protein degradation in the mouse 
ventral midbrain” [65] 
ID: “A review of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced changes in immunocompetence: 
1991 update” [66] 
Acrolein  
PD: “data suggests acrolein likely plays an important role in inducing PD pathology following 
bTBI by encouraging α-synuclein aggregation.” [67] 
ID: “Acrolein in cigarette smoke attenuates the innate immune responses mediated by 
surfactant protein D” [68] 
Air Pollution 
PD: “Traffic-related air pollution increased the risk of Parkinson's disease in Taiwan: A 
nationwide study” [69] 





ID: “air pollutants can affect different immune cell types such as particle-clearing 
macrophages, inflammatory neutrophils, dendritic cells that orchestrate adaptive immune 
responses and lymphocytes that enact those responses. Common themes that emerge are of 
the capacity of air pollutants to stimulate pro-inflammatory immune responses across 
multiple classes of immune cell. Air pollution can enhance T helper lymphocyte type 2 
(Th2) and T helper lymphocyte type 17 (Th17) adaptive immune responses, as seen in 
allergy and asthma, and dysregulate anti-viral immune responses.” [70] 
Aluminum  
PD: “Aluminum-containing antacids as a cause of idiopathic Parkinson's disease” [71] 
ID: “Aluminum as a CNS and Immune System Toxin Across the Life Span” [72] 
Arsenic 
PD: “Arsenic Induces Accumulation of α-Synuclein: Implications for Synucleinopathies and 
Neurodegeneration” [73] 
ID: “Arsenic immunotoxicity and immunomodulation by phytochemicals: potential relations to 
develop chemopreventive approaches” [74] 
Atrazine 
PD: “Identification of miRNA-7 as a regulator of brain-derived neurotrophic factor/α-synuclein 
axis in atrazine-induced Parkinson's disease by peripheral blood and brain microRNA 
profiling” [75] 
ID: “Long-term Immunotoxic Effects of Oral Prenatal and Neonatal Atrazine Exposure” [76] 
Cadmium  
PD: “Cadmium toxicity has been associated with learning disabilities and Parkinsonian 
symptoms in humans.” [77] 
ID: “Cadmium and chlorpyrifos inhibit cellular immune response in spleen of rats” [78] 
Carbon Monoxide 
PD: “Increased risk of Parkinson disease in patients with carbon monoxide intoxication: a 
population-based cohort study” [79] 
ID: “Chronic prenatal exposure to carbon monoxide results in a reduction in tyrosine 
hydroxylase-immunoreactivity and an increase in choline acetyltransferase-
immunoreactivity in the fetal medulla: implications for Sudden Infant Death Syndrome” 
[80] 
Carbon Tetrachloride 
PD: “Ever exposure to trichloroethylene (TCE) was associated with significantly increased risk 
of PD…..exposure to perchloroethylene (PERC) and carbon tetrachloride (CCl(4) ) tended 
toward significance (respectively: OR, 10.5; 95% CI, 0.97-113; p = 0.053; OR, 2.3; 95% 
CI, 0.9-6.1; p = 0.088). Results were similar for estimates of exposure duration and 
cumulative lifetime exposure..” [81] 
ID: “Carbon tetrachloride is immunosuppressive and decreases host resistance to Listeria 
monocytogenes and Streptococcus pneumoniae in female B6C3F1 mice.)” [82] 
Chlorpyrifos  
PD: “Chlorpyrifos-induced parkinsonian model in mice: Behavior, histopathology and 
biochemistry” [83] 
ID: “Cadmium and chlorpyrifos inhibit cellular immune response in spleen of rats” [78] 
Cobalt 
PD: “The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated 
mechanisms” [84] 





ID: “dermal sensitization to cobalt may increase the susceptibility of the lungs to inhaling 
cobalt. Mechanistically, this enhanced susceptibility involves changes in pulmonary DCs 
and ILCs.” [85] 
Copper Sulfate 
PD: “Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by manganese 
and copper” [86] 
ID: “Immunotoxicity of copper nanoparticle and copper sulfate in a common Indian 
earthworm” [87] 
Dichlorodiphenyltrichloroethane 
PD: “Dichlorodiphenyltrichloroethane (DDT) induced extracellular vesicle formation: a 
potential role in organochlorine increased risk of Parkinson's disease” [88] 
ID: “Exposures to the environmental toxicants pentachlorophenol (PCP) and 
dichlorodiphenyltrichloroethane (DDT) modify secretion of interleukin 1-beta (IL-1β) from 
human immune cells” [89] 
Hexachlorobenzene  
PD: “Although associations with other compounds were weaker, hexachlorobenzene (P = 
0.003) and α-chlordane (P = 0.007) were also related to Lewy pathology.” [90] 
ID: “Oral exposure of rats to HCB showed stimulatory effects on spleen and lymph node 
weights and histology, increased serum IgM levels, and an enhancement of several 
parameters of immune function.” [91] 
Inorganic Dust 
PD: “Exposure to inorganic dust was associated with increased risk of Parkinson's disease and 
Parkinsonian disorders” [92] 
ID: “immunologic aberrations occur in several inorganic dust diseases” [93] 
Lead 
PD: “The immunohistochemical approach has revealed that Pb-intoxicated Meriones show a 
significant increase of Tyrosine Hydroxylase (TH) levels within the Substantia Nigra 
compacta (SNc), Ventral Tegmental Area (VTA), Locus Coeruleus (LC), Dorsal Striatum 
(DS) and Medial Forebrain Bundle (MFB),” [94] 
ID: “Lead exposure can result in impaired immune function of T lymphocytes and erythrocytes 
in preschool children.” [95] 
Manganese 
PD: “Manganese-induced parkinsonism and Parkinson's disease” [96] 
ID: “SNc of the Mn-exposed animals showed an important decrease (67.58%) in the number of 
TH-immunopositive neurons.” [97] 
Mercury 
PD: “Mercury may play a role in the etiology of Parkinson disease and Grover's disease.” [98] 
ID: “Diphenyl diselenide protects against hematological and immunological alterations induced 
by mercury in mice” [99] 
N-hexane 
PD: “Chronic exposure to n-hexane contributes to induce onset of Parkinson's disease” [100] 
ID: “Severe testicular atrophy involving the seminiferous tubules with loss of the nerve growth 
factor (NGF) immunoreactive germ cell line was found. Total loss of the germ cell line was 
found in a fraction of animals up to 14 months post-exposure, indicating permanent 
testicular damage.  ... . Toluene and xylene were thus found to protect from n-hexane 
induced testicular atrophy.” [101] 






PD: “In logistic regression models, long-term exposure to NO2 increased PD risk overall (odds 
ratio (OR)=1.06 per 2.94μg/m3 increase, 95% CI=1.00-1.13).” [102] 
ID: “Acute nitrogen dioxide (NO2) exposure enhances airway inflammation via modulating 
Th1/Th2 differentiation and activating JAK-STAT pathway” [103] 
PCBs 
PD: “These quantitative data demonstrate an association between brain PCB levels and 
Parkinson's disease-related pathology. Furthermore, these data support epidemiological and 
laboratory studies reporting a link between PCB exposure and an increased risk for 
Parkinson's disease, including greater susceptibility of females.” [104] 
ID: “Exposure to PCBs suppresses the immune system, thereby increasing the risk of acquiring 
several human diseases.” [105] 
Perchloroethylene 
PD: “Ever exposure to trichloroethylene (TCE) was associated with significantly increased risk 
of PD (odds ratio [OR], 6.1; 95% confidence interval [CI] 1.2-33; p = 0.034), and exposure 
to perchloroethylene (PERC) and carbon tetrachloride (CCl(4) ) tended toward significance 
(respectively: OR, 10.5; 95% CI, 0.97-113; p = 0.053; OR, 2.3; 95% CI, 0.9-6.1; p = 
0.088).” [81] 
ID: “The mechanism of enhancing the PCA reaction is assumed to be that PCE increases IL-4 
production and PCE causes T helper (Th) 1/Th2-type helper T-cell imbalance and increases 
histamine release from excessively accumulated mast cells.” [106] 
Polybrominated Diphenyl Ethers  
PD: “isobaric tags for relative and absolute quantitation (iTRAQ) proteomics study of the 
striatum, which is the part of brain that is most intensively studied in PD pathogenesis, 
revealed that BDE-47 could induce neurotransmitter system disturbance, abnormal 
phosphorylation, mitochondrial dysfunction and oxidative stress.” [107] 
ID: “The results showed that after 24h of exposure, BDE-47 (>5 μM) and BDE-209 (>20 μM) 
induced cell apoptosis, increased intracellular reactive oxygen species (ROS) formation and 
depleted glutathione.” [108] 
Power Frequency EMF 
PD: “We finally demonstrate that ELF-MFs alter the expression of the alpha-synuclein, which 
is specifically stimulated upon ELF-MFs exposure via both direct miR-34 targeting and 
oxidative stress. Altogether, our data highlight the potential of the ELF-MFs to tune redox 
homeostasis and epigenetic control of gene expression in vitro and shed light on the 
possible mechanism(s) producing detrimental effects and predisposing neurons to 
degeneration” [109] 
ID: “The data demonstrate that MF in vivo exposure of female rats induces complex effects on 
the mitogenic responsiveness of T cells, which may lead to impaired immune surveillance 
after long-term exposure.” [110] 
Radiofrequency EMF 
PD: “GSM radiation seems to contribute to the Alzheimer’s and Parkinson’s disease pathogenic 
mechanisms…..changes in monomeric α-syn accumulation and multimerization, as well as 
induction of oxidative stress and cell death, were documented” [111] 
ID: “After 30 days of exposure time, 1 h/day EMF exposure resulted in significant decrease in 
immunoglobulin levels (IgA, IgE, IgM, and IgG); total leukocyte, lymphocyte, eosinophil 





and basophil counts; and a significant increase in neutrophil and monocyte counts. These 
changes were more increased in the group exposed to 2 h/day EMF.” [112] 
Radiotherapy 
PD: “Occupational exposure to chronic ionizing radiation increases risk of Parkinson's disease 
incidence in Russian Mayak workers” [113] 
ID: “various degrees of cognitive deficit can develop after much lower doses of ionizing 
radiation, as well…..A permanent deficit in neurogenesis, chronic microvascular 
alterations, and blood-brain barrier dysfunctionality are considered among the main 
causative factors. Chronic neuroinflammation and altered immune reactions in the brain, 
which are inherent complications of brain irradiation, have also been directly implicated in 
the development of cognitive decline after radiation.” [114] 
Silica 
PD: “the in vivo injury of neurochemicals occurred as the SiO2-NPs appeared to induce 
depleted dopamine in the striatum, and the down-regulation of tyrosine hydroxylase protein 
was the main contribution. These data demonstrate that SiO2-NPs possibly have a negative 
impact on the striatum and dopaminergic neurons as well as a potential risk for 
neurodegenerative diseases.” [115] 
ID: “toxicity of SiNPs to the immune system has received an increasing amount of attention. 
SiNPs may have toxic effects on phagocytes, particularly macrophages, dendritic cells 
(DCs) and T-lymphocytes. Additionally, the immunotoxicity of SiNPs to tissues and organs 
has been investigated in vivo.” [116] 
Titanium 
PD: “Our findings indicated that TiO2, depending on dose, can cause the destruction of 
dopaminergic neurons and consequently increase the risk of Parkinson's disease” [117] 
ID: “these results indicated that TiO2 could induce hematotoxicity, genotoxic, and 
immunotoxic alterations with exposure for long durations” [118] 
Trichloroethylene 
PD: “mice were intoxicated with trichloroethylene and tyrosine hydroxylase immunoreactivity 
was used to measure neuronal death in the substantia nigra pars compacta. Treated mice 
presented significant dopaminergic neuronal death in comparison with control mice 
(50%).” [119] 
ID: “Differential immunotoxicity induced by two different windows of developmental 
trichloroethylene exposure” [120] 
 
Category 5 
Chronic Restraint Stress 
PD: “Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: 
Possible role of chronic stress in the onset of Parkinson's disease” [121] 
ID: “Toll-like receptor 4 mediates chronic restraint stress-induced immune suppression” [122] 
Depression 
PD: “patients with depression are at risk of developing PD later in life.” [123] 
ID: “Both stress and depression were associated with the decreased cytotoxic T-cell and natural 
killer cell activities affecting the processes of the immune surveillance of tumours, and the 
events that modulate the development and the accumulation of somatic mutations and 
genomic instability.” [124] 
Life Stress 





PD: “Exposure to Early Life Stress Results in Epigenetic Changes in Neurotrophic Factor Gene 
Expression in a Parkinsonian Rat Model” [125] 
ID: “Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an 
acute psychological stressor in humans” [126] 
Posttraumatic Stress 
PD: “Our study was the first to demonstrate that both TBI and PTSD are independently 
associated with increased relative PD risk in a diverse nationwide cohort of military service 
veterans, and the first to suggest a potential modest synergistic excess risk in those with 
comorbid TBI/PTSD” [127] 
ID: “Posttraumatic stress and immune dissonance” [128]  
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